Search

Your search keyword '"Savio, V."' showing total 58 results

Search Constraints

Start Over You searched for: Author "Savio, V." Remove constraint Author: "Savio, V."
58 results on '"Savio, V."'

Search Results

2. POS0974 CARDIOVASCULAR OUTCOMES OF ANTI-TNF ALFA AND JAK INHIBITORS IN PATIENTS WITH RHEUMATOID AND PSORIATIC ARTHRITIS. REAL WORLD EVIDENCE AND INSIGHTS OF BIOBADASAR 3.0 REGISTRY

3. AB1666 CLUSTER ANALYSIS TO IDENTIFY PATIENT GROUPS AND ASSESS THE PRESENCE OF ADVERSE EVENTS. REAL WORLD EVIDENCE FROM THE BIOBADASAR 3.0 REGISTRY

4. AB1298 PATIENTS WITH AXIAL SPONDYLOARTHRITIS HAVE BETTER SARS-CoV-2 OUTCOMES COMPARED WITH PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE NATIONAL SAR-COVID REGISTRY

5. POS0660 SURVIVAL AND SAFETY OF BIOLOGICAL AND TARGETED SYNTHETIC THERAPIES. 10 YEARS OF REAL-LIFE DATA. BIOABASAR 3.0 REGISTRY

6. POS0655 SURVIVAL AND SAFETY OF BIOLOGICAL AND TARGETED SYNTHETIC THERAPIES AS REGARDS TO AGE GROUPS. BIOBADASAR 3.0 REGISTRY.

7. POS1199 IS PSORIATIC ARTHRITIS A RISK FACTOR FOR SEVERE COVID -19 INFECTION? DATA FROM THE ARGENTINIAN REGISTRY SAR-COVID

8. POS1200 DIFFERENCES BETWEEN THE FIRST AND THE SECOND WAVE OF SARS-COV-2 INFECTION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES IN ARGENTINA: DATA FROM THE SAR-COVID REGISTRY

9. AB1094 SAFETY AND EFFICACY OF VACCINES FOR SARS-CoV-2 IN PATIENTS WITH RHEUMATIC AND IMMUNE-MEDIATED INFLAMMATORY DISEASES: DATA FROM THE ARGENTINEAN REGISTRY SAR-CoVAC

10. POS1204 SARS-CoV-2 INFECTION AFTER VACCINATION IN PATIENTS WITH RHEUMATIC DISEASES FROM ARGENTINA

11. POS1238 GLUCOCORTICOIDS, RITUXIMAB AND THE PRESENCE OF INTERSTITIAL LUNG DISEASE ARE ASSOCIATED WITH POOR OUTCOMES OF THE SARS-COV-2 INFECTION IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE NATIONAL REGISTRY SAR-COVID.

12. PATIENTS WITH AXIAL SPONDYLOARTHRITIS HAVE BETTER SARS-COV-2 OUTCOMES COMPARED WITH PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM THE NATIONAL SAR-COVID REGISTRY.

13. AB0342 OBSTETRIC AND THROMBOTIC ANTIPHOSPHOLIPID SYNDROME: ARE THEY DIFFERENT ENTITIES?

15. POS1188 COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES: COMPARISON OF DATA FROM THE ARGENTINE REGISTRY (SAR-COVID), WITH THE LATIN AMERICAN AND GLOBAL REGISTRY (GLOBAL RHEUMATOLOGY ALLIANCE)

16. Levels of type I interferon in patients with systemic lupus erythematosus

19. CARDIOVASCULAR OUTCOMES OF ANTI-TNF ALFA AND JAK INHIBITORS IN PATIENTS WITH RHEUMATOID AND PSORIATIC ARTHRITIS. REAL WORLD EVIDENCE AND INSIGHTS OF BIOBADASAR 3.0 REGISTRY.

20. Evaluation of scale-adaptive simulation for transonic cavity flows

23. Emerging effects of early environmental factors over genetic background for type 1 diabetes susceptibility: Evidence from a nationwide Italian twin study

24. AB1097 The Impact of Systemic Lupus Erythematosus on Work Productivity: Data from Patients from the Province of Cordoba, Argentina

25. AB1103 Cumulative Rate and Factors Associated with Self-Reported Work Disability Among Patients with Systemic Lupus Erythematosus: Data from the Province of Cordoba, Argentina

28. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

29. An Unconventional Oral Candidiasis in an Immunocompetent Patient

30. Antimicrobial peptide human β-defensin-2 improves in vitro cellular viability and reduces pro-inflammatory effects induced by enteroinvasive Escherichia coli in Caco-2 cells by inhibiting invasion and virulence factors' expression

31. Antimicrobial Peptides Human Beta-Defensin-2 and -3 Protect the Gut During Candida albicans Infections Enhancing the Intestinal Barrier Integrity: In Vitro Study

32. Lactobacillus brevis CD2: Fermentation Strategies and Extracellular Metabolites Characterization

33. The Intestinal Biofilm of Pseudomonas aeruginosa and Staphylococcus aureus Is Inhibited by Antimicrobial Peptides HBD-2 and HBD-3

34. Q-switched Nd:YAG laser protects human keratinocytes from oxidative stress and inflammation via AhR-Nrf2 pathway.

35. Regulatory Ability of Lactiplantibacillus plantarum on Human Skin Health by Counteracting In Vitro Malassezia furfur Effects.

36. Oreoch-1: A Peptide from Oreochromis niloticus as a Potential Tool against Staphylococci.

37. Evaluation of Different Activity of Lactobacillus spp. against Two Proteus mirabilis Isolated Clinical Strains in Different Anatomical Sites In Vitro: An Explorative Study to Improve the Therapeutic Approach.

38. Soy, Rice and Oat Drinks: Investigating Chemical and Biological Safety in Plant-Based Milk Alternatives.

39. Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status.

40. In Vitro Evaluation of the Most Active Probiotic Strains Able to Improve the Intestinal Barrier Functions and to Prevent Inflammatory Diseases of the Gastrointestinal System.

41. An Unconventional Oral Candidiasis in an Immunocompetent Patient.

42. Antimicrobial peptide human β-defensin-2 improves in vitro cellular viability and reduces pro-inflammatory effects induced by enteroinvasive Escherichia coli in Caco-2 cells by inhibiting invasion and virulence factors' expression.

43. Decreased expression of Malassezia furfur virulence factors after Q-switched Nd:YAG laser irradiation.

44. Antimicrobial Peptides Human Beta-Defensin-2 and -3 Protect the Gut During Candida albicans Infections Enhancing the Intestinal Barrier Integrity: In Vitro Study.

45. Lactobacillus brevis CD2: Fermentation Strategies and Extracellular Metabolites Characterization.

46. Induction of Different Apoptosis Pathways by Two Proteus mirabilis Clinical Isolates Strains in Prostatic Epithelial Cells.

47. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus )-Pan-American League of Associations of Rheumatology (PANLAR).

48. Biofilm Formation and Immunomodulatory Activity of Proteus mirabilis Clinically Isolated Strains.

49. Beta-Defensin-2 and Beta-Defensin-3 Reduce Intestinal Damage Caused by Salmonella typhimurium Modulating the Expression of Cytokines and Enhancing the Probiotic Activity of Enterococcus faecium .

50. [Early systemic sclerosis].

Catalog

Books, media, physical & digital resources